Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models

Mary Sheu, Ashley J. Fowler, Jack Kao, Matthias Schmuth, Kristina Schoonjans, Johan Auwerx, Joachim W. Fluhr, Mao Qiang Man, Peter M. Elias, Kenneth R. Feingold

Research output: Contribution to journalArticle

Abstract

Activators of peroxisome proliferator activated receptor-α, a nuclear hormone receptor that heterodimerizes with retinoid X receptor, stimulate epidermal differentiation and inhibit proliferation. Here we determined the anti-inflammatory effects of peroxisome proliferator activated receptor-α agonists in models of irritant and allergic contact dermatitis produced in mouse ears by topical treatment with 12-O-tetradecanoylphorbol-13-acetate and oxazalone, respectively. As expected, 12-O-tetradecanoylphorbol-13-acetate treatment resulted in a marked increase in the thickness and weight of the ears and provoked an inflammatory cell infiltrate in the dermis. Topical treatment with three different peroxisome proliferator activated receptor-α agonists, clofibrate, WY 14643, or linoleic acid, 45 min and 4 h after 12-O-tetradecanoylphorbol-13-acetate application, resulted in a marked decrease in ear thickness and weight and a reduction in the number of inflammatory cells in the dermis. The reduction in inflammation by these peroxisome proliferator activated receptor-α agonists was of similar magnitude to that seen with a potent topical glucocorticoid, clobetasol. In contrast, stearic acid, a free fatty acid that does not activate peroxisome proliferator activated receptor-α, had no effect on the 12-O-tetradecanoylphorbol-13-acetate-induced inflammation. Moreover, clofibrate did not significantly alter ear thickness following 12-O-tetradecanoylphorbol-13-acetate treatment in peroxisome proliferator activated receptor-α-/- mice, indicating that the anti-inflammatory effect is mediated by peroxisome proliferator activated receptor-α. As tumor necrosis factor-α and interleukin-1α are major mediators of cutaneous inflammation we next used immunohistochemistry to determine whether the peroxisome proliferator activated receptor-α agonists reduce the levels of these cytokines in 12-O-tetradecanoylphorbol-13-acetate-treated skin. 12-O-tetradecanoylphorbol-13-acetate treatment resulted in an increase in tumor necrosis factor and interleukin-1α staining in the epidermis that was reduced by clofibrate treatment. Finally, clofibrate treatment also reduced ear thickness and weight in oxazalone-induced allergic dermatitis, a change that was accompanied by a reduction in inflammatory cells in the dermis and a decrease in tumor necrosis factor-α and interleukin-1α levels in the oxazalone-treated epidermis. These studies demonstrate that topically applied peroxisome proliferator activated receptor-α agonists possess receptor mediated, anti-inflammatory activity in both irritant and allergic contact dermatitis animal models. The anti-inflammatory properties of peroxisome proliferator activated receptor-α agonists, coupled with their anti-proliferative and pro-differentiating effects, suggest that they could be beneficial for the treatment of a variety of cutaneous diseases.

Original languageEnglish (US)
Pages (from-to)94-101
Number of pages8
JournalJournal of Investigative Dermatology
Volume118
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Dermatitis
Peroxisome Proliferator-Activated Receptors
Allergic Contact Dermatitis
Irritants
Tetradecanoylphorbol Acetate
Inflammation
Acetates
Clofibrate
Ear
Anti-Inflammatory Agents
Dermis
Interleukin-1
Tumor Necrosis Factor-alpha
Therapeutics
Epidermis
Clobetasol
Retinoid X Receptors
Weights and Measures
Inflammation Mediators
Skin

Keywords

  • Clofibrate
  • Epidermis
  • Nuclear hormone receptors

ASJC Scopus subject areas

  • Dermatology

Cite this

Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models. / Sheu, Mary; Fowler, Ashley J.; Kao, Jack; Schmuth, Matthias; Schoonjans, Kristina; Auwerx, Johan; Fluhr, Joachim W.; Man, Mao Qiang; Elias, Peter M.; Feingold, Kenneth R.

In: Journal of Investigative Dermatology, Vol. 118, No. 1, 2002, p. 94-101.

Research output: Contribution to journalArticle

Sheu, Mary ; Fowler, Ashley J. ; Kao, Jack ; Schmuth, Matthias ; Schoonjans, Kristina ; Auwerx, Johan ; Fluhr, Joachim W. ; Man, Mao Qiang ; Elias, Peter M. ; Feingold, Kenneth R. / Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models. In: Journal of Investigative Dermatology. 2002 ; Vol. 118, No. 1. pp. 94-101.
@article{e3d3bfa6ca504fdbbf748bfb70ff911f,
title = "Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models",
abstract = "Activators of peroxisome proliferator activated receptor-α, a nuclear hormone receptor that heterodimerizes with retinoid X receptor, stimulate epidermal differentiation and inhibit proliferation. Here we determined the anti-inflammatory effects of peroxisome proliferator activated receptor-α agonists in models of irritant and allergic contact dermatitis produced in mouse ears by topical treatment with 12-O-tetradecanoylphorbol-13-acetate and oxazalone, respectively. As expected, 12-O-tetradecanoylphorbol-13-acetate treatment resulted in a marked increase in the thickness and weight of the ears and provoked an inflammatory cell infiltrate in the dermis. Topical treatment with three different peroxisome proliferator activated receptor-α agonists, clofibrate, WY 14643, or linoleic acid, 45 min and 4 h after 12-O-tetradecanoylphorbol-13-acetate application, resulted in a marked decrease in ear thickness and weight and a reduction in the number of inflammatory cells in the dermis. The reduction in inflammation by these peroxisome proliferator activated receptor-α agonists was of similar magnitude to that seen with a potent topical glucocorticoid, clobetasol. In contrast, stearic acid, a free fatty acid that does not activate peroxisome proliferator activated receptor-α, had no effect on the 12-O-tetradecanoylphorbol-13-acetate-induced inflammation. Moreover, clofibrate did not significantly alter ear thickness following 12-O-tetradecanoylphorbol-13-acetate treatment in peroxisome proliferator activated receptor-α-/- mice, indicating that the anti-inflammatory effect is mediated by peroxisome proliferator activated receptor-α. As tumor necrosis factor-α and interleukin-1α are major mediators of cutaneous inflammation we next used immunohistochemistry to determine whether the peroxisome proliferator activated receptor-α agonists reduce the levels of these cytokines in 12-O-tetradecanoylphorbol-13-acetate-treated skin. 12-O-tetradecanoylphorbol-13-acetate treatment resulted in an increase in tumor necrosis factor and interleukin-1α staining in the epidermis that was reduced by clofibrate treatment. Finally, clofibrate treatment also reduced ear thickness and weight in oxazalone-induced allergic dermatitis, a change that was accompanied by a reduction in inflammatory cells in the dermis and a decrease in tumor necrosis factor-α and interleukin-1α levels in the oxazalone-treated epidermis. These studies demonstrate that topically applied peroxisome proliferator activated receptor-α agonists possess receptor mediated, anti-inflammatory activity in both irritant and allergic contact dermatitis animal models. The anti-inflammatory properties of peroxisome proliferator activated receptor-α agonists, coupled with their anti-proliferative and pro-differentiating effects, suggest that they could be beneficial for the treatment of a variety of cutaneous diseases.",
keywords = "Clofibrate, Epidermis, Nuclear hormone receptors",
author = "Mary Sheu and Fowler, {Ashley J.} and Jack Kao and Matthias Schmuth and Kristina Schoonjans and Johan Auwerx and Fluhr, {Joachim W.} and Man, {Mao Qiang} and Elias, {Peter M.} and Feingold, {Kenneth R.}",
year = "2002",
doi = "10.1046/j.0022-202x.2001.01626.x",
language = "English (US)",
volume = "118",
pages = "94--101",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models

AU - Sheu, Mary

AU - Fowler, Ashley J.

AU - Kao, Jack

AU - Schmuth, Matthias

AU - Schoonjans, Kristina

AU - Auwerx, Johan

AU - Fluhr, Joachim W.

AU - Man, Mao Qiang

AU - Elias, Peter M.

AU - Feingold, Kenneth R.

PY - 2002

Y1 - 2002

N2 - Activators of peroxisome proliferator activated receptor-α, a nuclear hormone receptor that heterodimerizes with retinoid X receptor, stimulate epidermal differentiation and inhibit proliferation. Here we determined the anti-inflammatory effects of peroxisome proliferator activated receptor-α agonists in models of irritant and allergic contact dermatitis produced in mouse ears by topical treatment with 12-O-tetradecanoylphorbol-13-acetate and oxazalone, respectively. As expected, 12-O-tetradecanoylphorbol-13-acetate treatment resulted in a marked increase in the thickness and weight of the ears and provoked an inflammatory cell infiltrate in the dermis. Topical treatment with three different peroxisome proliferator activated receptor-α agonists, clofibrate, WY 14643, or linoleic acid, 45 min and 4 h after 12-O-tetradecanoylphorbol-13-acetate application, resulted in a marked decrease in ear thickness and weight and a reduction in the number of inflammatory cells in the dermis. The reduction in inflammation by these peroxisome proliferator activated receptor-α agonists was of similar magnitude to that seen with a potent topical glucocorticoid, clobetasol. In contrast, stearic acid, a free fatty acid that does not activate peroxisome proliferator activated receptor-α, had no effect on the 12-O-tetradecanoylphorbol-13-acetate-induced inflammation. Moreover, clofibrate did not significantly alter ear thickness following 12-O-tetradecanoylphorbol-13-acetate treatment in peroxisome proliferator activated receptor-α-/- mice, indicating that the anti-inflammatory effect is mediated by peroxisome proliferator activated receptor-α. As tumor necrosis factor-α and interleukin-1α are major mediators of cutaneous inflammation we next used immunohistochemistry to determine whether the peroxisome proliferator activated receptor-α agonists reduce the levels of these cytokines in 12-O-tetradecanoylphorbol-13-acetate-treated skin. 12-O-tetradecanoylphorbol-13-acetate treatment resulted in an increase in tumor necrosis factor and interleukin-1α staining in the epidermis that was reduced by clofibrate treatment. Finally, clofibrate treatment also reduced ear thickness and weight in oxazalone-induced allergic dermatitis, a change that was accompanied by a reduction in inflammatory cells in the dermis and a decrease in tumor necrosis factor-α and interleukin-1α levels in the oxazalone-treated epidermis. These studies demonstrate that topically applied peroxisome proliferator activated receptor-α agonists possess receptor mediated, anti-inflammatory activity in both irritant and allergic contact dermatitis animal models. The anti-inflammatory properties of peroxisome proliferator activated receptor-α agonists, coupled with their anti-proliferative and pro-differentiating effects, suggest that they could be beneficial for the treatment of a variety of cutaneous diseases.

AB - Activators of peroxisome proliferator activated receptor-α, a nuclear hormone receptor that heterodimerizes with retinoid X receptor, stimulate epidermal differentiation and inhibit proliferation. Here we determined the anti-inflammatory effects of peroxisome proliferator activated receptor-α agonists in models of irritant and allergic contact dermatitis produced in mouse ears by topical treatment with 12-O-tetradecanoylphorbol-13-acetate and oxazalone, respectively. As expected, 12-O-tetradecanoylphorbol-13-acetate treatment resulted in a marked increase in the thickness and weight of the ears and provoked an inflammatory cell infiltrate in the dermis. Topical treatment with three different peroxisome proliferator activated receptor-α agonists, clofibrate, WY 14643, or linoleic acid, 45 min and 4 h after 12-O-tetradecanoylphorbol-13-acetate application, resulted in a marked decrease in ear thickness and weight and a reduction in the number of inflammatory cells in the dermis. The reduction in inflammation by these peroxisome proliferator activated receptor-α agonists was of similar magnitude to that seen with a potent topical glucocorticoid, clobetasol. In contrast, stearic acid, a free fatty acid that does not activate peroxisome proliferator activated receptor-α, had no effect on the 12-O-tetradecanoylphorbol-13-acetate-induced inflammation. Moreover, clofibrate did not significantly alter ear thickness following 12-O-tetradecanoylphorbol-13-acetate treatment in peroxisome proliferator activated receptor-α-/- mice, indicating that the anti-inflammatory effect is mediated by peroxisome proliferator activated receptor-α. As tumor necrosis factor-α and interleukin-1α are major mediators of cutaneous inflammation we next used immunohistochemistry to determine whether the peroxisome proliferator activated receptor-α agonists reduce the levels of these cytokines in 12-O-tetradecanoylphorbol-13-acetate-treated skin. 12-O-tetradecanoylphorbol-13-acetate treatment resulted in an increase in tumor necrosis factor and interleukin-1α staining in the epidermis that was reduced by clofibrate treatment. Finally, clofibrate treatment also reduced ear thickness and weight in oxazalone-induced allergic dermatitis, a change that was accompanied by a reduction in inflammatory cells in the dermis and a decrease in tumor necrosis factor-α and interleukin-1α levels in the oxazalone-treated epidermis. These studies demonstrate that topically applied peroxisome proliferator activated receptor-α agonists possess receptor mediated, anti-inflammatory activity in both irritant and allergic contact dermatitis animal models. The anti-inflammatory properties of peroxisome proliferator activated receptor-α agonists, coupled with their anti-proliferative and pro-differentiating effects, suggest that they could be beneficial for the treatment of a variety of cutaneous diseases.

KW - Clofibrate

KW - Epidermis

KW - Nuclear hormone receptors

UR - http://www.scopus.com/inward/record.url?scp=0036153739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036153739&partnerID=8YFLogxK

U2 - 10.1046/j.0022-202x.2001.01626.x

DO - 10.1046/j.0022-202x.2001.01626.x

M3 - Article

C2 - 11851881

AN - SCOPUS:0036153739

VL - 118

SP - 94

EP - 101

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 1

ER -